KALA BIO, Inc. (NASDAQ: KALA) filed a Current Report on Form 8-K on November 12, 2026, announcing a 1-for-30 reverse stock split of its common stock. The split is effective as of 4:05 p.m. (Delaware time) on November 13, 2026, and will be implemented through a Certificate of Amendment to the Company’s Restated Certificate of Incorporation.
The reverse stock split will automatically combine every 30 shares of issued and outstanding common stock into one share. The par value per share remains unchanged at $0.001. The Company reports that the split will reduce the total number of shares outstanding from 19,339,786 to approximately 644,659 shares.
Under the terms of the split, no fractional shares will be issued. Stockholders who would have received fractional shares will instead receive a cash payment based on the closing price of the stock on the Nasdaq Capital Market on November 12, 2026. The Company’s authorized share capital remains unchanged at 1,500,000,000 shares.
Proportional adjustments will be made to outstanding equity awards, warrants, and convertible securities, including the exercise or conversion price and the number of shares issuable under the Company’s 2009 Employee, Director and Consultant Equity Incentive Plan, the Amended and Restated 2017 Equity Incentive Plan, and the Amended and Restated 2017 Employee Stock Purchase Plan.
Following the split, the Common Stock will begin trading on a split-adjusted basis when the market opens on November 16, 2026. The trading symbol will remain “KALA,” and the new CUSIP number will be 483119400.
